



Attorney Docket No. UAB-14402/22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert P. Kimberly

Serial No.: 09/807,501

Group Art Unit: 1634

Filing Date: May 23, 2001

Examiner: Jehanne Souaya Sitton

For: POLYMORPHISM IN FAS PROMOTER AND FAS LIGAND PROMOTER

DECLARATION OF ROBERT P. KIMBERLY
UNDER 37 CFR 1.132Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

I, Robert P. Kimberly, declare as follows:

1. I am the inventor of the invention disclosed in the above-identified application for patent.

2. My curriculum vitae is attached detailing my experiences in basic and therapeutic genetic research.

3. I state that Systemic Lupus Erythematosus (SLE) is a prototypic autoimmune disease, recognized as such by myself and others expert in the field of molecular genetics at the time of filing of the present application for patent. Although the etiology of SLE is unclear, it is well-recognized that SLE is a disease of complex multifactorial origin, having a significant genetic component. The following references explicitly state that SLE is considered to be a prototype for autoimmune diseases generally, supporting my assertion:

Vyse, T.J. and Kotzin, B.L., Genetic Susceptibility to Systemic Lupus Erythematosus, Ann. Rev. Immunol., 1998, 16:261-92. ("Systemic lupus erythematosus (SLE) is considered to be the prototypic systemic autoimmune disease." p. 262, first paragraph)

Kotzin, B.L., Systematic Lupus Erythematosus, Cell, 1996, 85:303-306 ("Systematic Lupus Erythematosus (SLE) is considered to be the prototypic systemic autoimmune disease." p.303, first sentence)

Pisetsky, D.S., Systematic Lupus Erythematosus, Curr. Opin. Immunol., 1991, 3:917-923, ("Systematic lupus erythematosus is a prototypic autoimmune disease..." - abstract)

4. I state that statistical analysis on the data in Table 1 was performed and that the data showing that -844 is T in 56% and C in 44% of SLE patients are statistically significant from controls.

5. I state that the term "putative haplotype" used in the heading of Table 5 is an art recognized term indicating that a combination of analytical methods was used. Generally, in order to find haplotypes, genetic material is sequenced directly, and alleles represented in each individual are determined. The haplotype, or combination of alleles on a single strand of genetic material, can be determined by a) cloning each strand followed by direct sequencing, b) direct assignment in individuals with only one heterozygous site and only two possible haplotypes, and c) by inference, based on data from a) and b) and using statistical methods known in the art, of the most probable haplotypes in individuals who have multiple heterozygous sites. The term 'putative' is used to indicate the use of each of these approaches.

6. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and

that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date

5/27/09

Robert P. Kimberly
Robert P. Kimberly



THE UNIVERSITY OF ALABAMA AT BIRMINGHAM
SCHOOL OF MEDICINE
FACULTY CURRICULUM VITAE

Date: March 1, 2004

PERSONAL INFORMATION:

Name: Robert Parker Kimberly

Citizenship: U.S.

Social Security Number: 044-38-3679

Home Address: 2045 Magnolia Ridge, Birmingham, AL 35243

Phone: (205) 967-8348

RANK/TITLE
Professor, Department of Medicine
Professor, Department of Microbiology
Professor, Department of Cell Biology
Professor, Department of Genetics
Director, Division of Clinical Immunology and Rheumatology
Director and Senior Scientist, UAB Arthritis and Musculoskeletal Center
Senior Scientist, Biomedical Implant Center
Senior Scientist, Cell Adhesion and Matrix Research Center
Senior Scientist, Comprehensive Cancer Center
Senior Scientist, Center for Health Promotion
Senior Scientist, Center for Metabolic Bone Disease
Senior Scientist, Center for Outcomes and Effectiveness Research
And Education

Business Address: The University of Alabama at Birmingham
1900 University Boulevard, THH 429
Birmingham, AL 35294-0006

Phone: (205) 934-5306

Fax: (205) 934-1564

E-mail address: Robert.Kimberly@ccc.uab.edu

HOSPITAL APPOINTMENTS:

University of Alabama Hospitals

PROFESSIONAL CONSULTANTSHIPS: Scientific Advisory Board, EluSys Therapeutics, Inc.

EDUCATION:

Institution	Degree	Year
Princeton University, Princeton, NJ	AB	1968
University of Oxford, Oxford, England	BA, MA	1970
Harvard Medical School, Boston, MA	MD	1973

MILITARY SERVICE: United States Public Health Service, 1975-1977

LICENSURE:

State of Alabama, 20592
 State of New York, 130593
 State of New Jersey, MA 33346
 State of Maryland, D18174 (inactive)
 State of Pennsylvania, 15566E (inactive)
 District of Columbia, 9145 (inactive)

BOARD CERTIFICATION:

American Board of Internal Medicine (#53941), June 1976
 Rheumatology (ABIM, #53941), June 1978

POSTDOCTORAL TRAINING:

Year	Degree	Institution
1973-75	Intern and Asst. Resident in Medicine	Hospital of the University of Pennsylvania, Philadelphia, PA
1975-77	Clinical Associate	Arthritis and Rheumatism Branch, NIAMS, NIH, Bethesda, MD
1977-79	Fellow in Rheumatic Diseases	The New York Hospital and Hospital for Special Surgery, New York, NY

PROFESSIONAL AND ACADEMIC:

Professor, Department of Medicine, The University of Alabama at Birmingham, 1996-present
 Professor, Department of Microbiology, The University of Alabama at Birmingham, 1996-present
 Professor, Department of Cell Biology, The University of Alabama at Birmingham, 2003-present.
 Professor, Department of Genetics, The University of Alabama at Birmingham, 2003-present.
 Director, Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, 1996-present
 Director, Senior Scientist, Arthritis and Musculoskeletal Center, The University of Alabama at Birmingham, 1996-present
 Senior Scientist, Comprehensive Cancer Center, The University of Alabama at Birmingham, 1996-present
 Senior Scientist, Metabolic Bone Diseases Center, The University of Alabama at Birmingham, 1997-present
 Senior Scientist, Center for Health Promotion, The University of Alabama at Birmingham, 1998-present
 Senior Scientist, Biomedical Implant Center, The University of Alabama at Birmingham, 1998-present
 Senior Scientist, Center for Outcomes and Effectiveness Research Education, The University of Alabama at Birmingham, 2000-present.

PROFESSIONAL AND ACADEMIC: (continued)

Senior Scientist, Cell Adhesion and Matrix Research Center , The University of Alabama at Birmingham, 2002 – present.

Cornell Arthritis and Musculoskeletal Diseases Center

Program Director, January 1994-September 1996

Director, Biomedical Research Component, January 1988-September 1996

Director, HSS/Cornell Flow Cytometry Facility, Cornell University, January 1986-June 1994

Program Director, Rheumatology Research Training, Cornell University, June 1995-September 1996

Professor, Graduate Program in Immunology, Cornell University Graduate School of Medical Sciences, July 1991- September 1996

Professor of Medicine, Cornell University Medical College, New York, NY, July 1991- September 1996

Attending Physician, The New York Hospital and The Hospital for Special Surgery, New York, NY, July 1991-September 1996

Associate Professor of Medicine, Cornell University Medical College, New York, NY, July 1984-June 1991

Associate Attending Physician , The New York Hospital and The Hospital for Special Surgery, New York, NY, July 1984-June 1991

Assistant Professor of Medicine, Cornell University Medical College, New York, NY, July 1979-June 1984

Assistant Attending Physician, The New York Hospital and The Hospital for Special Surgery, New York, NY, July 1979- June 1984

HONORS, AWARDS AND FELLOWSHIPS:

2002- "Best Doctors in America" Recognition

2002 Outstanding Speaker Award, Arthritis Foundation

2001 Arthritis Foundation Postdoctoral Fellowship Program Hero Award

1996 Howard L. Holley Professor of Medicine, University of Alabama at Birmingham

1980-81 Andrew W. Mellon Teacher-Scientist Award, Cornell University

1977-80 Postdoctoral Fellow of The Arthritis Foundation

1970 The New College Book Prize, University of Oxford

1968-70 Rhodes Scholarship, University of Oxford

1968 Senior Book Prize in Biology, Princeton University

1968 Phi Beta Kappa, Princeton University

PROFESSIONAL SOCIETIES:

Association of American Physicians

American Society for Clinical Investigation

American Federation for Medical Research

American College of Rheumatology, Fellow

American College of Physicians, Fellow

American Association of Immunologists

Clinical Immunology Society

Molecular Medicine Society

American Association for the Advancement of Science

Association of American Rhodes Scholars

Alabama Society for Rheumatic Diseases

New York Rheumatism Association

The Harvey Society

The Kunkel Society

COUNCILS, COMMITTEES, AND PROFESSIONAL ACTIVITIES:

Director, UAB FOCIS Center of Excellence in Clinical Immunology	2003-
Member, Institutional Review Board - Human Studies Advisory Committee, The University of Alabama at Birmingham	2003-
Member, Council of Postdoctoral Education, The University of Alabama at Birmingham	2003-
Member, Internal Advisory Committee, P20 and U24 Oral Health Research Infrastructure proposals, School of Dentistry	2003-
CEO Search Committee, UAB Research Foundation	2003-
Medical Student Review Panelist, Howard Hughes Medical Institute Arthritis Foundation	2003-
Board of Trustees (National)	2003-
CEO Search Committee	2003
Board of Trustees (Alabama Chapter)	2001-
Medical and Scientific Committee (National)	
Member	1997-99
Vice Chair	1999-00
Chair	2001-03
Blue Ribbon Committee on Research	2000
Alliance for Lupus Research	
Scientific Advisory Board Member	2003-
Member, Ex Officio	2001-03
Internal Advisory Board Member, UAB Center for Health Promotion	2002-
Member, Frederick Gardner Cottrell Postdoctoral Enhancement Award Committee, The University of Alabama at Birmingham	2001-
Councilor, Clinical Immunology Society	2001-
Association of American Physicians Committee, UAB Dept of Medicine	1999-
Internal Advisory Committee, Program Project Grant, Molecular Immunopathogenesis of Demyelinating Disease	1999
International Union of Immunological Societies/WHO/Arthritis Foundation ANA Subcommittee & Liaison to Arthritis Foundation	1999
Member, Department of Oral Biology Search Committee, UAB Joint Health Sciences	1999
Chair, Department of Genetics Search Committee, UAB School of Medicine	1998
Joint Publication Committee, American College of Rheumatology	1998-00
Chair, Arthritis and Rheumatism Committee	1998-00
Member, Hematology - Oncology Search Committee, UAB Dept of Medicine	1998
Assessment Task Force, UAB Department of Medicine	1998-
Center Management Committee, UAB Injury Control Research Center	1997-
Internship Interviewing Committee, UAB School of Medicine	1997-
Child Health Research Center Advisory Committee, UAB Department Of Pediatrics	1997-
Research Advisory Committee (Med-RAC), UAB School of Medicine	1997-

COUNCILS, COMMITTEES, AND PROFESSIONAL ACTIVITIES (continued)

Steering Committee, UAB Comprehensive Oral Health Research Center of Discovery	1996-97
Steering Committee, UAB/Sankyo Program in Rheumatic Diseases	1996-
Steering Committee, UAB Metabolic Bone Diseases Center	1996-
Allocation Task Force Committee, UAB Department of Medicine	1996-
Inflammation Strategic Planning Committee, UAB School of Medicine	1996
Medical Student Enrichment Program Preceptor, UAB School of Medicine	1996-
Abstract Selection Chair, ACR 1997 Annual Scientific Meeting	1996
Medical Advisory Committee, Wegener's Granulomatosis Foundation	1996-
Program Director, Rheumatology Research Training, Cornell University Medical College	1995-96
Accreditation Council Graduate Medical Education Appeals Panel, Rheumatology	1994-00
Paul Klemperer Award Committee, New York Academy of Medicine	1993-97
Research Council, American College of Rheumatology	1993-96
Research Executive Board, Hospital for Special Surgery	1991-96
Molecular Biology Steering Committee, Hospital for Special Surgery	1990-96
Cornell Arthritis and Musculoskeletal Diseases Center	1988-96
Program Director (1994-96)	
Director, Biomedical Research Component (1988-96)	
Medical Board, Hospital for Special Surgery	1987-89
Executive Committee, New York Rheumatism Association	1987-93
Vice President (1990), President - Elect (1991), President (1992-93)	
Director, HSS/Cornell Flow Cytometry Facility	1986-94
Council Member, NE Region, American College of Rheumatology	1986-92
President, Northeast Region Council (1990-91)	
Medical Advisory Board, The SLE Foundation, Inc., NY, NY	1986-93
SLE Study Group, American College of Rheumatology	1986-92
President (1991-92)	
Professional Meetings Committee, American College of Rheumatology	1985-90
Postgraduate Education Advisory Committee, Cornell University Medical College	1985-96
Clinical Competence Committee, New York Hospital	1985-96
Program Chairman, NE Region American Rheumatism Association	1985
Institutional Animal Care and Use Committee, Hospital for Special Surgery	1984-96
Medical and Scientific Committee, New York Arthritis Foundation	1984-90
Laboratory Safety Committee, Hospital for Special Surgery	1984-90
Exhibits Committee, American Rheumatism Association	1982-85
Faculty Advisor, Cornell University Medical College	1980-96
Internship Interviewing Committee, New York Hospital	1980-93
Study Sections, Review Committees and Advisory Committees	
External Review Committee, Children's Hospital Research Foundation Cincinnati, OH	1998, 2003
Peer Review Chair, The Arthritis Foundation (National Office)	1999-00
NIAID Task Force on Immunology (Chapter XI)	1997
NIAMS Centers Working Group I	1996
Member, General Medicine A Study Section (NIH)	1994-98
(Chairman, 10/96 - 6/98)	
Member, General Medicine A Study Section (NIH)	1986-90
Cell Biology Subcommittee, The Arthritis Foundation (National Office)	1992

Fellowship Committee, The Arthritis Foundation (National Office)	1989-91
Medical and Scientific Committee, NY Arthritis Foundation	1984-90
(Chairman, Subcommittee on Research Guidelines)	1985-86
Medical Advisory Board, The SLE Foundation, Inc., NY, NY	1986-93
Ad Hoc Reviewer, Special Study Sections and Site Visit Committees	
NIH/NIDDK R24 Special Review Panel	2004
NIH/NIAID R21 Special Review Panel	2003
NIH/NIAMS Collaborative Approaches to Genetics	2003
NIH/NIAMS R03 Special Review Panel	2003
NIH/NIAMS R21 Special Emphasis Panel (Chair)	2002
NIH/NIAMS Extramural Roundtable: Rheumatic Diseases	2001
NIH/NIAMS P30 RDCC Review Committee	2000
NIH/NIAMS P20 Planning Grant Review Committee	1999
NIH/NIAMS P50 Program Project Review (Chairman)	1998
NIH/NIAID Gene Therapy Special Study Section	1996
NIH/NIAMS Rare Disease Registry (Chairman)	1994
NIH/DRR General Clinical Research Centers	1984-87
NIH/NIAMS Multipurpose Arthritis and Musculoskeletal Disease Centers	1984-96
The Arthritis Society (Canada)	
Arthritis and Rheumatism Council (UK)	
The Lupus Foundation of America	
NIH SBIR Program	

EDITORIAL BOARDS/AD HOC REVIEWER:

Arthritis and Rheumatism
 American Journal of Kidney Diseases
 American Journal of Medicine
 Annals of Internal Medicine
 Cancer Research
 Clinical & Diagnostic Laboratory Immunology
 Clinical and Experimental Rheumatology
 Clinical Pharmacology and Therapeutics
 Clinical Immunology and Immunopathology
 Current Opinion in Rheumatology
 Genes and Immunity
 Immunogenetics
 Journal of Clinical Investigation
 Journal of Experimental Medicine
 Journal of Laboratory and Clinical Medicine
 Journal of Leukocyte Biology
 Journal of Infectious Diseases
 Journal of Immunology
 Journal of Pediatrics
 Journal of Rheumatology
 Kidney International
 New England Journal of Medicine
 Proc. Society Experimental Biology and Medicine

Scandinavian Journal of Rheumatology
Science

INVITED LECTURES AND VISITING PROFESSORSHIPS:

Visiting Professor, Long Island College Hospital, SUNY Downstate Medical School, 1995
 John Jay Visiting Professorship, UMDNJ-Robert Wood Johnson Medical School, 1995
 Invited speaker, NYU Course in Advanced Rheumatology, "Wegener's Granulomatosis",
 March 1996
 Invited speaker, Immunology series, Mayo Clinic and Research Foundation, June 1996
 Invited speaker, FASEB Summer Conference, "Fc Receptors as a member of MIRR," July 1996
 Invited speaker, NYRA-ACR Rheumatology Review Course, September 1996
 Invited speaker, 7th International Meeting on ANCA and ANCA-related diseases, October 1996
 Invited speaker, Rheumatology Series, University of Connecticut School of Medicine, March 1997
 Invited speaker, UAB/Montgomery Internal Medicine Residency Program, "SLE: Bringing the
 Bench to the Bedside", August 1997
 Invited speaker, Southern Medical Association, "SLE: Bringing the Bench to the Bedside", August
 1997
 Invited speaker, NIAID/ORD Workshop on Systemic Vasculitis, "ANCA and Neutrophils: The Fcγ
 Hypothesis", September 1997
 Invited speaker, Rheumatology-on-the Beach, "Fc Receptors: Risk Factors for Autoimmune
 Disease", September 1997
 Invited speaker, New York University and Hospital for Joint Diseases, "Fc Receptors - Insights into
 Nephritis and Vasculitis", October 1997
 Rheumatology and Immunology Series, Medical University of South Carolina, "Fc Receptor
 Function and The Pro-Adhesive Phenotype: Differential Mechanisms of Activation", November
 1997
 Invited speaker, University of Alabama-Tuscaloosa, "Fc Receptors: Insights into Nephritis and
 Vasculitis", January 1998
 Rheumatology Series, University of North Carolina, "Fc Receptors: Risk Factors for Nephritis",
 April 1998
 Invited Speaker, ALA/ATS International Conference, "ANCA-Associated Vasculitis", April 1998
 Invited Speaker, 8th International Meeting on ANCA and ANCA Related Diseases, "Engagement of
 Neutrophil FcγRIIa and FcγRIIIb", April 1998
 Invited Speaker, EULAR Postgraduate Conference, "Molecular Biology", August 1998
 Invited Speaker, Janice M. Wiles Lecture on SLE, "Antibody Receptors: Insights into Genetic Risks
 for Systemic Lupus Erythematosus", University of Massachusetts, October 1998
 Invited Speaker, University of Colorado, "Mechanisms of Receptor Diversity - The Ins and The
 Outs", February 1999
 Invited Speaker, Colorado Rocky Mountain Society for Rheumatic Diseases, "Antibody Receptors:
 Insights into Genetic Risks for Systemic Lupus Erythematosus", February 1999
 Invited Speaker, Dartmouth Medical School, "Receptor Diversity - The Ins and The Outs",
 February 1999
 Invited Speaker, ACR Innovative Therapies, "Outline of a Definite Study to Test a Responder
 Marker Hypothesis in Rheumatoid Arthritis", March 1999

INVITED LECTURES AND VISITING PROFESSORSHIPS: (continued)

Invited Speaker, Oklahoma Lupus Foundation, "New Insights into the Role of Antibodies in Lupus", April 1999

University of Pittsburgh Arthritis Institute Visiting Professor, April 1999

Immunology Series, "FcR Receptors: The Ins and the Outs for Host Defense"

Rheumatology Grand Rounds, "ANCAs: Markers or Mediators?"

Medical Grand Rounds, "SLE: Heritable Factors for Susceptibility and Severity"

Invited Speaker, 12th Annual Symposium, Duke University Medical Center, "The Role of Fc Receptors in Immune Cell Function", May 1999

Invited Speaker, Vanderbilt University School of Medicine Rheumatology Retreat, "SLE Genes and Receptors", May 1999

Ogryzlo Visiting Professor, University of Toronto, "SLE: Heritable Factors for Susceptibility and Severity", June 1999

Invited Speaker, AF-ACR-NIAM Arthritis Research '99, August 1999

Invited Speaker, University of Michigan Rheumatology Rounds, "The Role of Fc Receptors in Immune Cell Function", November 1999

William K. Ishmael Lectureship and Oklahoma Rheumatology Association's Annual Scientific Meeting, "Candidate Genes in SLE", February 2000

Invited Speaker, Gordon Research Conference: Drug Carriers in Medicine and Biology, "Endogenous immunoglobulin receptors: natural variants and implications for Ig-based biologics", February 2000

Invited Speaker, New York University School of Medicine Seminar in Advanced Rheumatology, "Fc Receptors in SLE", March 2000

Invited Speaker, University of Alabama Chief Resident's Society Meeting, "Systemic Lupus: the Impact of the New Genetics", March 2000

Invited Speaker, 9th International Vasculitis / ANCA Workshop, "Fc Receptors and Neutrophil Activation", Groningen, The Netherlands, April 2000

Invited Speaker, Annual European Congress of Rheumatology (EULAR 2000), "Genome-wide Screening in Rheumatic Diseases", Nice, France, June 2000

Invited Speaker, Edward W. Boland Rheumatology Visiting Professor, Mayo Foundation, "FcR Receptors: The Ins and the Outs for Host Defense" and "ANCAs: Markers or Mediators?", November 2000

Invited Speaker, Emory University Pathology Conference, "FcR Receptors: The Ins and the Outs for Host Defense", November 2000

Invited Speaker, University of Chicago, Rheumatology Rounds, "Fc gamma R: The Ins and the Outs" and Medical Grand Rounds "Lupus Genetics: Pathways and Pitfalls", February 2001

Invited Speaker, New York University and Hospital for Joint Diseases, Rheumatology Rounds, "BlyS – Tangent or Target?", April 2001

Moderator, Federation of Clinical Immunology Societies (FOCIS) Meeting, "Non-MHC Polymorphism & Disease", May 2001

Invited Speaker, Lupus Genetics Conference-Oklahoma Medical Research Foundation, "SCOR Tribulations and Triumphs", September 2001

Co-chair, AAI Experimental Biology 2002, "Translating the Genome", April 2002.

Invited Speaker, 19th Annual Rheumatology at the Beach, "B Lymphocyte Stimulating Factor - a Target or Tangent for SLE?", September 2002

Invited Speaker, Global Arthritis Research Network, "Fc Receptors as a Genetic risk Factor in Autoimmune Disease, September 2002

Invited Speaker, American Society for Histocompatibility and Immunogenetics, "Plenary 7: Fc Receptors and Signaling - FcR Polymorphism and Post-engagement Signaling", October 2002
Moderator, 2002 Annual Scientific Meeting of the American College of Rheumatology Meeting, "Mapping Susceptibility Loci for Rheumatic Disease, October 2002
Invited Speaker, Pfizer Visiting Professor, Washington Hospital Center, Georgetown University, and Uniformed Services Health Sciences Center, "Autoimmunity in SLE";
"Immunology of SLE-Implications for Therapy";
"Fc Receptor Biology and Autoimmune Diseases";
"Immunological Approaches to the Treatment of SLE", January 2003.
Invited Speaker, New York University School of Medicine, "Genetics of SLE: The Hot Stuff", March 2003
Invited Speaker, American College of Rheumatology Advances in Therapeutics, "Fc Receptors: Pharmacogenetics", March 2003
Invited Speaker, Metro Atlanta Rheumatology Society, "BLyS: Target or Tangent", April 2003
Invited Speaker, Protein Design Laboratories, "Fc receptors in Disease and Therapy", February 2004
Invited Speaker, Southern Society for Clinical Investigation, "Systemic Vasculitis: Mechanisms of Injury", February, 2004.
Invited Speaker, CIS Autoimmunity School, "Genetics of Autoimmune Diseases", March 2004
Invited Speaker, Advances in Targeted Therapies, "Lessons Learned from Analyses of SLE Susceptibility Genes", April 2004

CURRENT GRANT SUPPORT:

NIH R01 AR33062-22

Robert P. Kimberly, Principal Investigator
Mononuclear Phagocyte Function in Immunologic Diseases

NIH R01 AR42476-11

Robert P. Kimberly, Principal Investigator
Systemic Vasculitis: Host Factors in Tissue Injury

NIH P60 AR48095-03

Robert P. Kimberly, Principal Investigator
NIAMS Multidisciplinary Clinical Research Center

NIH P30 AR48311-03

Robert P. Kimberly, MD, Principal Investigator
Rheumatic Disease Core Center

NIH P01 AR49084-02

Robert P. Kimberly, MD, Principal Investigator
Program Project in the Genetics of SLE

NIH T32 AR07450-22

Robert P. Kimberly, Principal Investigator
Training Program in Rheumatic Diseases Research

NIH R01 AI/AR49569-04

Jeffrey C. Edberg, PhD, Principal Investigator

Genetic Polymorphisms in Wegener's Granulomatosis

SANKYO Program in Rheumatic Disease and Cancer Research
William J. Koopman, MD, Principal Investigator

BIBLIOGRAPHY:**MANUSCRIPTS:**

1. Lubow BK, Kimberly RP, Button WH, Kimberly JR: An empirical approach to work behavior, interaction and rehabilitation. *Human Organization* 28: 303, 1969.
2. Kimberly RP: Rhythmic patterns in human interaction. *Nature* 228: 88-90, 1970.
3. Kimberly RP, Holden AL, Bamborough P: Response characteristics of pigeon forebrain cells to visual stimulation. *Vision Research* 11:475-478, 1971.
4. Kimberly RP, Plotz PH: Aspirin-induced depression of renal function. *N Engl J Med* 296: 418-424, 1977.
5. Kimberly RP, Bowden RE, Keiser HR, Plotz PH: Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. *Am J Med* 64: 804-807, 1978.
6. Kimberly RP, Gill JR Jr, Bowden RE, Keiser HR, Plotz PH: Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. *Ann Intern Med* 89: 336-341, 1978.
7. Kimberly RP: Renal prostaglandins in systemic lupus erythematosus. *Lancet* ii: 553-555, 1978.
8. Kimberly RP, Brandstetter RD: Exacerbation of phenylbutazone-related renal failure by indomethacin. *Arch Intern Med* 138: 1171-1172, 1978.
9. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM: Increased risk of malignancy in sicca syndrome. *Ann Intern Med* 89: 888-892, 1978.
10. Kimberly RP, Sherman RL, Mouradian J, Lockshin MD: Apparent acute renal failure associated with therapeutic aspirin and ibuprofen administration. *Arthritis Rheum* 22: 281-285, 1979.
11. Frank MM, Hamburger MI, Lawley TJ, Kimberly RP, Plotz PH: Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. *N Engl J Med* 300: 518-523, 1979.
12. Plotz PH, Kimberly RP, Guyer RL, Segal DM: Stable model immune complexes produced by bivalent affinity labeling haptens: in vivo survival. *Molecular Immunology* 16: 721-725, 1979.
13. Karsh J, Kimberly RP, Stahl NI, Plotz PH, Decker JL: Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus. *Arthritis Rheum* 23: 1401-1404, 1980.

14. Plotz PH, Kimberly RP: Acute effects of aspirin and acetaminophen on renal function. Symptom Current Views on Aspirin and Acetaminophen. Arch Intern Med 141: 343-348, 1981.
15. Kimberly RP, Lockshin MD, Sherman RL, McDougal JS, Inman RD, Christian CL: High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med 70: 817-824, 1981.
16. Kimberly RP, Lockshin MD, Sherman RL, Beary JF, Mouradian J, Cheigh JS: End-stage lupus nephritis: Clinical course to and outcome on dialysis. Medicine 60: 277-287, 1981.
17. Perez HD, Kimberly RP, Kaplan HB, Edelson H, Inman RD, Goldstein IM: Effect of high-dose methylprednisolone infusion on polymorphonuclear leukocyte function in patients with systemic lupus erythematosus. Arthritis Rheum 24: 641-647, 1981.
18. Reynolds JC, Inman RD, Kimberly RP, Chuong JH, Kovacs JE, Walsh MB: Acute pancreatitis in systemic lupus erythematosus: report of twenty cases and a review of the literature. Medicine 61: 25-32, 1982.
19. Hamburger MI, Lawley TJ, Kimberly RP, Plotz PH, Frank MM: A serial study of reticuloendothelial system Fc γ receptor functional activity in systemic lupus erythematosus. Arthritis Rheum 25: 48-54, 1982.
20. Parris TM, Kimberly RP, Inman RD, McDougal JS, Gibofsky A, Christian CL: Defective Fc γ receptor mediated mononuclear phagocyte function in lupus nephritis. Ann Intern Med 97: 526-532, 1982.
21. Kimberly RP, Parris TM, Inman RD, McDougal JS: Dynamics of mononuclear phagocyte system Fc γ receptor function in systemic lupus erythematosus. Relation to disease activity and circulating immune complexes. Clin Exp Immunol 51: 261-268, 1983.
22. Kimberly RP, Lockshin MD, Sherman RL, Mouradian J, Saal S: Reversible "end-stage" renal disease in systemic lupus erythematosus. Am J Med 74: 361-368, 1983.
23. Kimberly RP, Ralph P: Endocytosis by the mononuclear phagocyte system and autoimmune disease. Am J Med 74: 481-493, 1983.
24. Kimberly RP, Gibofsky A, Salmon JE, Fotino M: Impaired Fc-mediated mononuclear phagocyte system clearance in HLA-DR2 and MT1-positive normals. J Exp Med 157: 1698-1703, 1983.
25. Bussel JB, Kimberly RP, Inman RD, Schulman I, Cunningham-Rundles C, Smithwick E, O'Malley J, Barandun S, Hilgartner MW: Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Mechanism of action and development of resistance. Blood 62: 480-486, 1983.
26. Schned ES, Inman RD, Parris TM, Kimberly RP, Redecha PB, Christian CL: Serial circulating immune complexes and mononuclear phagocyte system function in infective endocarditis. J Lab Clin Med 102: 947-959, 1983.

27. Kimberly RP, Salmon JE, Bussel JB, Crow MK, Hilgartner MW: Modulation of mononuclear phagocyte function by intravenous gammaglobulin. *J Immunol* 132: 745-750, 1984.
28. Kimberly RP, Inman RD, Bussel JB, Polk JR, Hilgartner MW: Modulation of mononuclear phagocyte system function and circulating immune complexes by lyophilized concentrates in patients with classic hemophilia. *Clin Immunol Immunopathol* 31: 321-330, 1984.
29. Salmon JE, Kimberly RP, Gibofsky A, Fotino M: Defective mononuclear phagocyte function in systemic lupus erythematosus: Dissociation of Fc γ receptor-ligand binding and internalization. *J Immunol* 133: 2525-2531, 1984.
30. Porges A, Bussel J, Kimberly R, Schulman I, Pollack M, Pandey J, Barandun S, Hilgartner M: Elevation of platelet-associated antibody levels in patients with chronic idiopathic thrombocytopenic purpura expressing the B8 and/or DR3 allotypes. *Tissue Antigens* 26: 132-137, 1985.
31. Salmon JE, Kimberly RP, Gibofsky A, Fotino M: Altered phagocytosis by monocytes from HLA-DR2 and DR3-positive healthy adults is Fc γ receptor specific. *J Immunol* 136: 3625-3630, 1986.
32. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC: Treatment of refractory immune thrombocytopenic purpura with an anti-Fc receptor antibody. *N Engl J Med* 314: 1236-1239, 1986.
33. Kimberly RP, Meryhew NL, Runquist OA: Mononuclear phagocyte function in SLE. I. Bipartite Fc- and complement-dependent dysfunction. *J Immunol* 137: 91-96, 1986.
34. Meryhew NL, Kimberly RP, Messner RP, Runquist OA: Mononuclear phagocyte system in SLE. II. A kinetic model of immune complex handling in systemic lupus erythematosus. *J Immunol* 137: 97-102, 1986.
35. Salmon JE, Kimberly RP: Phagocytosis of Concanavalin A-treated erythrocytes is mediated by the Fc γ receptor. *J Immunol* 137: 456-462, 1986.
36. Clarkson SB, Kimberly RP, Valinsky JE, Witmer MD, Bussel JB, Nachman RL, Unkeless JC: Blockade of clearance of immune complexes by an anti-Fc γ receptor monoclonal antibody. *J Exp Med* 164: 474-489, 1986.
37. Salmon JE, Kapur S, Kimberly RP: Gammaglobulin for intravenous use induces an Fc γ receptor-specific decrement in phagocytosis by blood monocytes. *Clin Immunol Immunopathol* 43: 23-33, 1987.
38. Greisman SG, Redecha PB, Kimberly RP, Christian CL: Differences among immune complexes: Association of C1q in SLE immune complexes with renal disease. *J Immunol* 138: 739-745, 1987.

39. Kimberly RP, Meryhew NL, Runquist OA: Isolated complement-dependent mononuclear phagocyte system dysfunction in rheumatoid arthritis: occurrence in normocomplementemia. *J Immunol* 138: 4165-4168, 1987.
40. Salmon JE, Kapur S, Kimberly RP: Opsonin independent ligation of Fc receptors: The 3G8-bearing receptors on neutrophils mediate the phagocytosis of Concanavalin A-treated erythrocytes and non-opsonized *Escherichia coli*. *J Exp Med* 166: 1798-1813, 1987.
41. Kimberly RP, Tappe N, Merriam LT, Redecha PB, Edberg JC, Schwartzman S, Valinsky JE: Carbohydrates on human FcγR: Interdependence of the classical IgG and nonclassical lectin binding sites on human FcγRIII expressed on neutrophils. *J Immunol* 142: 3923-3930, 1989.
42. Salmon JE, Kapur S, Meryhew NL, Runquist OA, Kimberly RP: High dose pulse intravenous methylprednisolone enhances Fcγ receptor-mediated mononuclear phagocyte function in systemic lupus erythematosus. *Arthritis Rheum* 32: 717-725, 1989.
43. Kimberly RP, Salmon JE, Edberg JC, Gibofsky A: The role of Fcγ receptors in mononuclear phagocyte system function. *Clin Exp Rheumatol* 7: 103-108, 1989.
44. Edberg JC, Redecha PB, Salmon JE, Kimberly RP: Human FcγRIII (CD16). Isoforms with distinct allelic expression, extracellular domains and membrane linkages on PMN and NK cells. *J Immunol* 143: 1642-1649, 1989.
45. Kimberly RP, Edberg JC, Merriam LT, Clarkson SB, Unkeless JC, Taylor RP: The in vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees. *J Clin Invest* 84: 962-970, 1989.
46. Salmon JE, Edberg JC, Kimberly RP: FcγRIII on human neutrophils: Allelic variants have functionally distinct capacities. *J Clin Invest* 85: 1287-1295, 1990.
47. Kimberly RP, Ahlstrom JW, Click ME, Edberg JC: The glycosyl phosphatidylinositol-linked FcγRIIIPMN mediates transmembrane signaling events distinct from FcγRII. *J Exp Med* 171: 1239-1255, 1990.
48. Edberg JC, Barinsky M, Redecha PB, Salmon JE, Kimberly RP: FcγRIII expressed on cultured monocytes is an N-glycosylated protein distinct from FcγRIII expressed on natural killer cells. *J Immunol* 144: 4729-4734, 1990.
49. Edberg JC, Salmon JE, Kimberly RP: Preferential expression of human FcγRIII (CD16) in paroxysmal nocturnal hemoglobinuria. Discordant expression of glycosyl phosphatidylinositol-linked proteins. *J Clin Invest* 86: 58-67, 1991.
50. Salmon JE, Brogle N, Edberg JC, Kimberly RP: Fcγ receptor III induces actin polymerization and primes phagocytosis mediated by FcγRII. *J Immunol* 146: 997-1004, 1991.
51. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM: Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity and mechanism of effect. *Blood* 77: 1884-1893, 1991.

52. Clark MR, Stuart SG, Kimberly RP, Ory PA, and Goldstein IM: A single amino acid distinguishes the high responder from the low responder form of Fcγ receptor II on human monocytes. *Eur J Immunol* 21: 1911-1916, 1991.
53. Odin JA, Edberg JC, Painter C, Kimberly RP, Unkeless JC: Regulation of phagocytosis and [Ca²⁺]_i flux by distinct regions of an Fcγ receptor. *Science* 254: 1785-1788, 1991.
54. Edberg JC, Kimberly RP, Taylor RP: Functional characterization of non-human primate erythrocyte immune adherence receptors: Implications for the uptake of immune complexes by the cells of the mononuclear phagocyte system. *Eur J Immunol* 22: 1333-1339, 1992.
55. Salmon JE, Brogle N, Edberg JC, Kimberly RP: Allelic polymorphisms of human Fcγ receptor IIA and Fcγ receptor IIIB: Independent mechanisms for differences in human phagocyte function. *J Clin Invest* 89: 1274-1281, 1992.
56. Edberg JC and Kimberly RP: Receptor specific probes for the study of individual Fcγ receptor function. *J Immunol Methods* 148: 179-187, 1992.
57. Porges AJ, Redecha PB, Doebele R, Pan LC, Salmon JE, Kimberly RP: Novel Fcγ receptor I gene products in human mononuclear cells. *J Clin Invest* 90: 2102-2109, 1992.
58. Edberg JC, Salmon JE, Kimberly RP: Functional capacity of FcγRIII on neutrophils. *Immunologic Research* 11: 239-251, 1992.
59. Porges AJ, Beattie SL, Ritchlin C, Kimberly RP, and Christian CL: Patients with systemic lupus erythematosus at risk for *Pneumocystis carinii* pneumonia. *J Rheumatol* 19: 1191-1194, 1992.
60. Salmon JE, Brogle N, Brownlie C, Edberg JC, Kimberly RP, Chen BX, Erlanger BF: Human mononuclear phagocytes express adenosine A1 receptors: A novel mechanism for differential regulation of Fcγ receptor function. *J Immunol* 151: 2775-2785, 1993.
61. Edberg JC and Kimberly RP: Modulation of Fcγ and complement receptor function by the glycosylphosphatidylinositol-anchored form of Fcγ RIII. *J Immunol* 152: 5826-5835, 1994.
62. Indik ZK, Hunter S, Huang MM, Chien P, Pan XQ, Levinson AI, Kimberly RP, Schreiber AD: The high affinity Fcγ receptor (CD64) induces phagocytosis in the absence of its cytoplasmic domain. *Expt Haematol* 22: 599-606, 1994.
63. Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL, Kimberly RP: Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via FcγRIIA. *J Immunol* 153: 1271-1280, 1994.
64. Kimberly RP, Salmon JE, Edberg JC: Receptors for immunoglobulin G. Molecular diversity and implications for disease. *Arthritis Rheum* 38: 306-314, 1995.

65. Salmon JE, Millard SS, Brogle N, Kimberly RP: Fc γ receptor IIIb enhances Fc γ RIIa function in an oxidant-dependent and allele-sensitive manner. *J Clin Invest* 95: 2877-2885, 1995.
66. Edberg JC, Lin CT, Lau D, Unkeless JC, Kimberly RP: The [Ca²⁺]_i dependence of human Fc γ receptor initiated phagocytosis. *J Biol Chem* 270: 22301-22307, 1995.
67. Huang R, Cioffi J, Kimberly R, Edberg J, Mayer L: B cell differentiation factor-induced human B cell maturation: Stimulation of intracellular calcium release. *Cellular Immunol* 164: 227-233, 1995.
68. Chang DJ, Siegel ME, Moon JJ, Edberg JC, Salmon JE, Kimberly RP: Differential regulation of Fc γ receptor isoforms: Implications for therapeutic intervention. *Am J Therapeutics* 2: 777-781, 1995.
69. Salmon JE, Millard S, Schacter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Kimberly RP: Fc γ RIIA alleles are heritable risk factors for lupus nephritis in African-Americans. *J Clin Invest* 97: 1348-1354, 1996.
70. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP: A novel polymorphism of Fc γ RIIIa (CD16) alters receptor function and predisposes to autoimmune disease. *J Clin Invest* 100:1059-1070, 1997.
71. Haseley LA, Wisneiski JJ, Denburg MR, Michael-Grossman AR, Ginzler EM, Gourley MF, Hoffman JH, Kimberly RP, Salmon JE: Antibodies to C1q in systemic lupus erythematosus: Characteristics and relation to Fc γ RIIA alleles. *Kidney Intl* 52: 1375-1380, 1997.
72. Edberg JC, Kimberly RP: Cell-type specific glycoforms of Fc γ RIIIa (CD16): Differential ligand binding. *J Immunol* 159:3849-3857, 1997.
73. Kocher M, Siegel ME, Edberg JC, Kimberly RP: Cross-linking of Fc γ RIIa and Fc γ RIIIb induces different proadhesive phenotypes on human neutrophils. *J Immunol* 159: 3940-3948, 1997.
74. Edberg JC, Wainstein E, Wu J, Csernok E, Sneller MC, Hoffman GS, Keystone EC, Gross WL and Kimberly RP: Analysis of Fc γ RII gene polymorphisms in Wegener's Granulomatosis. *Exp Clin Immunogenetics* 14:183-195, 1997.
75. Edberg JC, Moon J, Chang D, and Kimberly RP: Differential regulation of human neutrophil Fc γ RIIa (CD32) and Fc γ RIIIb (CD16) induced Ca²⁺ transients. *J Biol Chem* 273:8071-8079, 1998.
76. Maresco D, Blue L, Culley L, Kimberly RP, Anderson C, and Theil K: Localization of FCGR1 encoding Fc γ RI in primates: Molecular evidence for two pericentric inversions during the evolution of human chromosome 1. *Cytogenetics Cell Genetics*. 82:71-74, 1998.
77. Raman C, Kuo A, Deshane J, Litchfield DW and Kimberly RP: Regulation of casein kinase 2 by direct interaction with cell surface receptor CD5. *J Biol Chem* 273:19183-19189, 1998.

78. Raman C and Kimberly RP: Differential CD5-dependent regulation of CD5-associated CK2 activity in mature and immature T cells: Implication on TCR/CD3-mediated activation. *J Immunol* 161:5817-5820, 1998.
79. Kocher M, Edberg JC, Fleit HB, and Kimberly RP: Anti-neutrophil cytoplasmic antibodies (ANCA) preferentially engage Fc γ RIIIb on human neutrophils. *J Immunol* 161:6909-6914, 1998.
80. Bidwell J, Keen L, Gallagher G, Kimberly RP, Huizinga T, McDermott M, Oksenberg J, McNicholl J, Pociot F, Hardt C, Epplen C, D'Alfonso S: Cytokine gene polymorphism in human disease: on-line databases. *Genes Immun* 1:3-19, 1999.
81. Bidwell J, Keen L, Wood N, Morse H, Olomolaiye O, Laundry G, Gallagher G, Kimberly RP, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S: The Human Cytokine gene nucleotide sequence alignment and cytokine gene polymorphism databases 1999. *Nucleic Acids Research*, 1999.
82. Edberg JC, Yee AMF, Rakshit D, Chang DJ, Gokhale JA, Indik Z, Schreiber AD and Kimberly RP: The cytoplasmic domain of the Fc γ RIa alters the functional properties of the Fc γ RI- γ -chain receptor complex. *J Biol Chem* 274:30328-30333, 1999.
83. Wu J, Edberg JC, Gibson AW, Tsao B and Kimberly RP: Single-nucleotide polymorphisms of T cell receptor ζ chain in patients with Systemic Lupus Erythematosus. *Arthritis Rheum* 42:2601-2605, 1999.
84. Li XR, Chong AS, Wu J, Roebuck KA, Kumar A, Parrillo JE, Rapp UR, Kimberly RP, Williams JW, Xu X: Transcriptional regulation of Fas gene expression by GA-binding protein and AP-1 in T cell antigen receptor. CD3 complex-stimulated T cells. *J Biol Chem* 274: 35204-10, 1999.
85. Stein M-P, Edberg JC, Kimberly RP, Mangan EK, Bharadwaj D, Mold C, DuClos TW: C-reactive protein binding to Fc γ RIIa on human monocytes and neutrophils is allele specific. *J Clin Invest* 105:369-376, 2000.
86. Gray-McGuire C, Moser KL, Gaffney PM, Kelly J, Yu H, Olson JM, Jedrey CM, Jacobs KB, Kimberly RP, Neas BR, Rich SS, Behrens TW, Harley JB: Genome scan of human systemic lupus erythematosus by regression model evidence of linkage and epistasis at 4p16-15.2. *Am J Hum Genet.* 67:1460-1469, 2000.
87. Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, Bastian HM, Kimberly RP and Zhou T: Cutting Edge: A role for B lymphocyte stimulator (BLyS) in Systemic Lupus Erythematosus. *J Immunol*, 166:6-10, 2001.
88. Kimberly RP: Research advances in Systemic Lupus Erythematosus. *JAMA* 285:650-652, 2001.

89. Yee LJ, Tang J, Gibson AW, Kimberly RP, van Leeuwen DJ, Kaslow RA: Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic Hepatitis C Infection. *Hepatology* 33:708-712, 2001.
90. Gibson AW, Edberg JC, Wu J, Westendorp RGJ, Huizinga TWJ, Kimberly RP: Novel single nucleotide polymorphisms in the distal IL10 promoter affect IL10 production and enhance the risk of SLE. *J Immunol* 166:3915-3922, 2001.
91. DuClos TW, Mold C, Edberg JC, Kimberly RP: Response: Human C-Reactive Protein does not bind to FcγRIIIa on phagocytic cells. *J Clin Invest* 107: 642, 2001.
92. Chatham WW, Kimberly RP: Treatment of lupus with corticosteroids. *Lupus* 10:140-147, 2001.
93. Ichikawa K, Liu W, Wang Z, Liu D, Koopman WJ, Kimberly RP and Zhou T: Tumoricidal activity of a novel anti-human DR5 monoclonal antibody with hepatocyte cytotoxicity. *Nat Med* 7:954-960, 2001.
94. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S. Cytokine gene polymorphism in human disease: on-line databases, supplement 1. *Genes Immun* 2:61-70, 2001.
95. Wu J, Edberg JC, Gibson AW, Kimberly RP. Conservation of FcεRI gamma chain coding region in normals and in SLE patients. *Lupus* 11:42-5, 2002.
96. Su K, Wu J, Edberg J, McKenzie S, Kimberly RP: Genomic organization of classical human low-affinity Fcγ receptor genes. *Genes Immun* 3:S51-6, 2002.
97. Alarcon G, McGwin, Jr, G, Petri M, Reveille J D, Ramsey-Goldman R, Kimberly R P: Baseline characteristics of a multiethnic lupus cohort: PROFILE. *Lupus* 11:95-101, 2002.
98. Edberg JC, Langeveld CD, Wu J, Moser KL, Kaufman KM, Kelly J, Bansal V, Brown WM, Salmon JE, Rich SS, Harley JB, Kimberly RP: Genetic linkage and association of Fcγ receptor IIIA (CD 16A) on chromosome 1q23 with human systemic lupus erythematosus. *Arthritis Rheum* 46:2132-40, 2002.
99. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. *Genes Immun* 3:14-9, 2002.
100. Davis RS, Dennis Jr G, Odom MR, Gibson AW, Kimberly RP, Burrows PD, Cooper MD. Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. *Immunol Rev* 190:123-136, 2002.
101. Zhou T, Mountz JD, Kimberly RP. Immunobiology of tumor necrosis factor receptor superfamily. *Immunol Res* 26:323-36, 2002.

102. Kimberly RP, Wu J, Gibson AW, Su K, Qin H, Li X, Edberg JC. Diversity and duplicity: human Fcγ receptors in host defense and autoimmunity. *Immunol Res* 26:177-89, 2002.
103. Haukim N, Bidwell JL, Smith AJ, Keen LJ, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. *Genes Immun* 3:313-30, 2002.
104. Edberg JC, Qin H, Gibson AW, Yee AM, Redecha PB, Indik ZK, Schreiber AD, Kimberly RP. The CY domain of the FcγRIα alpha-chain (CD64) alters gamma-chain tyrosine-based signaling and phagocytosis. *J Biol Chem* 277:41287-93, 2002.
105. Sanchez ML, Alarcon GS, McGwin G Jr, Fessler BJ, Kimberly RP. Can the weighted criteria improve our ability to capture a larger number of lupus patients into observational and interventional studies? A comparison with the American College of Rheumatology criteria. *Lupus* 12:468-70, 2003.
106. Wu J, Metz C, Xu X, Abe R, Gibson A, Edberg J, Cooke J, Cooper G, Kimberly RP. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters fas ligand expression: A candidate background gene in African American systemic lupus erythematosus patients. *J Immunol* 170:132-138, 2003.
107. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. *Oncogene* 22:2034-44, 2003.
108. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R. The level of BlyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. *Ann Rheum Dis* 62:168-171, 2003.
109. Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T, Wang Z, Liu D, Mountz J, Ohtsuki M, Koopman W, Kimberly R, Zhou T. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. *J Immunol* 171:1061-1069, 2003.
110. Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, Li X, Koopman WJ, Kimberly RP. FcγRs modulate cytotoxicity of anti-Fas antibodies: Implications for agonistic antibody-based therapeutics. *J Immunol* 171:562-568, 2003.
111. Li X, Wu J, Carter R, Edberg J, Su K, Cooper G, Kimberly R. A novel polymorphism in Fcγ receptor IIb (CD32B) transmembrane region alters receptor signaling. *Arthritis Rheum* 48:3242-3252, 2003.
112. Tanaka S, Edberg JC, Chatham WW, Fassina G, Kimberly RP. Fc gamma RIIIb allele-sensitive release of alpha-defensins: anti-neutrophil cytoplasmic antibody-induced release of chemotaxins. *J Immunol* 171:6090-6096, 2003.
113. Vassilopoulos D, Younossi ZM, Hadziyannis E, Boparai N, Yen-Lieberman B, His E, Villa-Forte A, Ball E, Kimberly RP, Calabrese LH. Study of host and virological factors of patients

with chronic HCV infection and associated laboratory or clinical autoimmune manifestations. Clin Exp Rheumatol 21: S101-111,2003.

114. Liu W, Szalai A, Zhao L, Liu D, Martin F, Kimberly RP, Zhou T, Carter R. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum, in press, 2004.
115. Zhou T, Wang H, Luo D, Rowe T, Wang Z, Hogan RJ, Qiu S, Bunzel RJ, Huang G, Voss TG, Kimberly RP, Luo M. Anti-viral activity of monoclonal antibodies against a receptor binding domain of SARS coronavirus spike protein. J Virol, in press, 2004.
116. Su K, Wu J, Edberg JC, Li X, Ferguson P, Cooper GS, Langefeld C, Kimberly RP. A promoter haplotype of the ITIM-bearing FcγRIIb alters receptor expression and associate with autoimmunity. I. Regulatory *FCGR2B* polymorphisms and their association with systemic lupus erythematosus. J Immunol, in press, 2004.
117. Su K, Li X, Edberg JC, Wu J, Ferguson P, Kimberly RP. A promoter haplotype of the ITIM bearing FcγRIIb alters receptor expression and associate with autoimmunity. II. Differential binding for GATA4 and YY1 transcription factors and correlated receptor expression and function. J Immunol, in press, 2004.
118. Huizinga TWJ, Pisetsky DS, Kimberly RP. Associations, populations and the truth. Recommendations for genetic association studies in Arthritis and Rheumatism. Arthritis Rheum, in press, 2004.

Manuscripts submitted but not yet accepted

1. Zhou T, Wang H, Luo D, Rowe T, Wang Z, Hogan RJ, Qiu S, Bunzel RJ, Huang G, Mishra V, Liu D, Zhao L, Lin C, Ding L, Voss TG, Kimberly RP, Luo M. Specific N-protein signatures of SARS-associated coronavirus infection. J Clin Microbiol, revisions requested.
2. Yang X, Kimberly RP, Wang J, Liu C, Grizzle WE, Hsu HC, Yu SH, Liu Z, Kim H, Barnes S, Koopman WJ, Zhou T, Mountz JD, Zhang HG. Cleavage of p53-vimentin complex enhances TRAIL mediated apoptosis of rheumatoid arthritis synovial fibroblasts. J Biol Chem, revisions requested.
3. Wu J, McCrory MA, Xie F, Fan ZQ, Zakharkin SO, George V, Lange E, Langefeld C, Allison DB, Cooper GS, Kimberly RP, Szalai AJ. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene influence promoter activity and associate with serum CRP. Submitted.
4. Edberg JC, Wainstein E, Kocher M, Wu J, Sneller C, Hoffman GS, Keystone EC, Gross WL, Salmon JE and Kimberly RP: Fcγ Receptor alleles associate with renal dysfunction in Wegener's Granulomatosis. Submitted.
5. Wu J, Edberg JC, Mangan E and Kimberly RP: Characterization of polymorphisms in the Fas promoter and the association with systemic lupus erythematosus. Submitted.

Other Publications (letters and invited commentaries)

1. Plotz PH, Kimberly RP, Gill JR Jr, Seaman WE: Effects of salicylates on creatinine clearance. *British Medical Journal* 2 (6032): 4221, 1976.
2. Kimberly RP, Plotz PH: Aspirin and renal function. *N Engl J Med* 296: 1168-1169, 1977.
3. Kimberly RP, Gill JR Jr, Plotz PH: Aspirin and renal function. *Ann Intern Med* 90: 274-275, 1979.
4. Kimberly RP, Bressman S, Tapia L, Lockshin MD: Presumptive autonephrectomy in scleroderma. *Arthritis Rheum* 22: 305, 1979.
5. Kimberly RP: Treatment of lupus nephritis with combined therapy. *N Engl J Med* 300: 564-565, 1979.
6. Frank MM, Hamburger MI, Lawley TJ, Kimberly RP, Plotz PH: Fc-receptor dysfunction in lupus. *N Engl J Med* 300: 1486-1487, 1979.
7. Kimberly RP: Renal changes in systemic lupus erythematosus. *Arch Int Med* 139: 1062, 1979.
8. Kimberly RP, Weinberg H, Rudd E: Large reduction in renal function associated with cimetidine. *Arthritis Rheum* 23: 614-615, 1980.
9. Kimberly RP: Piroxicam, a new nonsteroidal anti-inflammatory agent. An invited commentary. *Pharmacotherapy* 2: 90, 1982.
10. Kimberly RP, Lockshin MD, Sherman RL, Cheigh JS: End stage renal disease in systemic lupus erythematosus. *N Engl J Med* 308: 1537-1539, 1983.
11. Kimberly RP, Bussel JB, Hilgartner MW: Hemophilia, antihemophilic factor and immune complexes. *Ann Intern Med* 100: 915-916, 1984.
12. Kimberly RP: Immune complex diseases. *Clinical Immunol Today*, edited by RA Good, 14: 1-3, 1985.
13. Kimberly RP: Lupus: Approaches to treatment. *Immunopathology Immunotherapy Letters* 1: 6-8, 1985.
14. Kimberly RP, Salmon JE, Gibofsky A: Methyldopa and reticuloendothelial function. *N Engl J Med* 314: 248-249, 1986.
15. Kimberly RP: Glucocorticoids. *Current Opinion in Rheumatology* 1: 92-97, 1989.
16. Kimberly RP: Steroids. *Current Opinion in Rheumatology* 2: 510-517, 1990.
17. Kimberly RP: Of mice and men: Insights into the complexity of mononuclear phagocyte system blockade provided by autoimmune mouse strains. *J Lab Clin Med* 117: 173-, 1991.

18. Kimberly RP: Mechanisms of action, dosage schedules, and side effects of steroid therapy. *Current Opinion in Rheumatology* 3: 373-379, 1991.
19. Kimberly RP: Glucocorticoid therapy for rheumatic diseases. *Current Opinion in Rheumatology* 4: 325-331, 1992.
20. Mysler E, Paget SA, Kimberly RP: Cipro reactions masquerading as lupus flares. *Arthritis Rheum* 37: 1112-1113, 1994.
21. Kimberly RP: Glucocorticoids. *Current Opinion in Rheumatology* 6: 273-280, 1994.

BOOKS:

Books and Monograph Chapters

1. Button WH, Kimberly JR, Lubow BK, Kimberly RP: A conceptual framework for the analysis of work behavior in sheltered workshops. *Region II Rehabilitation Research Institute, Studies in Behavior and Rehabilitation, No. 1*, Cornell University, Ithaca, New York, 1969.
2. Lubow BK, Kimberly RP, Button WH, Kimberly JR: Client behavior in sheltered workshops: two case studies. *Region II Rehabilitation Research Institute, Studies in Behavior and Rehabilitation, No.2*, Cornell University, Ithaca, New York, 1969.
3. Kimberly RP, Plotz PH: Renal vascular autoregulation: "Set-point" modulation by renal prostaglandins, in: *Controversies in Nephrology 1980*, edited by GE Schreiner and JF Winchester, Georgetown University Hospital, Washington, DC, 1980, pp 262-272.
4. Kimberly RP: Lupus erythematosus, in: *Manual of Rheumatology and Outpatient Orthopedic Disorders*, edited by JF Beary, CL Christian, TP Sculco and A Gibofsky, Little, Brown & Co., Boston, 1981, pp 167-181; 1987, pp 172-186; and 1993, pp 219-233.
5. Salmon J, Kimberly RP: Rheumatology formulary, in: *Manual of Rheumatology and Outpatient Orthopedic Disorders*, edited by JF Beary, CL Christian, TP Sculco and A Gibofsky, Little, Brown and Co., Boston, 1981, pp 321-333; 1987, pp 339-356; and 1993, pp 470-496.
6. Kimberly RP: Pulse methylprednisolone in systemic lupus erythematosus. in: *Systemic Lupus Erythematosus*, edited by GRV Hughes, *Clinics in Rheumatic Diseases* 8: 261-278, 1982.
7. Kimberly RP: Nonsteroidal anti-inflammatory drugs and colchicine, in: *Clinical Management of Poisoning and Drug Overdose*, edited by LM Haddad and JF Winchester, W.B. Saunders Company, Philadelphia, 1983, pp 586-592 and 1990, 921-930.
8. Kimberly RP: Anti-inflammatory drugs and the kidney in systemic lupus erythematosus and other arthropathies: "Set-point" modulation of renal function, in: *Adv. Inflammation Research*, edited by GP Velo and KD Rainsford, 6: 119-128, 1983.

9. Kimberly RP: Dietary strategies in the management of arthritis. in: Arthritis and the Elderly, edited by RW Moskowitz and MR Haug, Springer Publishing Co., New York, 1985, pp 109-122.
10. Kimberly RP: Steroid use in lupus erythematosus. in: Systemic Lupus Erythematosus, edited by RG Lahita, John Wiley and Sons, New York, 1987, pp 889-922.
11. Kimberly RP: Immune complexes in rheumatic diseases. in: Immunology of the Rheumatic Diseases, edited by DS Pisetsky and R Snyderman, Rheumatic Disease Clinics of North America 13(3): 583-596, 1987.
12. Kimberly RP: Treatment: Corticosteroids and nonsteroidal anti-inflammatory drugs. in: Systemic Lupus Erythematosus, edited by JH Klippel, Rheumatic Disease Clinics of North America 14(1): 203-221, 1988.
13. Kimberly RP, Plotz PH: Aspirin and salicylates including sulfasalazine. in: Textbook of Rheumatology, edited by WN Kelley, ED Harris, Jr, S Ruddy and CB Sledge, WB Saunders Co, Philadelphia 1989, pp 739-764.
14. Kimberly RP: Lupus erythematosus: systemic and localized forms. in: Textbook of Internal Medicine, edited by WN Kelley, JB Lippincott Co, Philadelphia, 1989, pp 996-1003.
15. Kimberly RP: Management of SLE, polymyositis, and overlap syndromes. in: Textbook of Internal Medicine, edited by WN Kelley, JB Lippincott Co, 1989, Philadelphia, pp 1100-1103.
16. Kimberly RP: Systemic lupus erythematosus. in: Textbook of Therapeutic Medicine for Practicing Physicians, edited by AN Samiy, Lea & Febiger, Philadelphia, 1992.
17. Kimberly RP: Systemic lupus erythematosus. in: Current Therapy in Allergy, Immunology and Rheumatology, edited by LM Lichtenstein and AS Fauci, BC Decker/Mosby-Year Book, St Louis, MO, 1992, pp 189-194.
18. Kimberly RP: Systemic lupus erythematosus. in: Rheumatic Disorders, edited by SA Paget and TR Fields, Andover Medical Publishers/Butterworth-Heinemann, New York, 1992, pp 151-160.
19. Lockshin MD, Kimberly RP, and Levy RA. Insuficiencia renal aguda nas doencas do colageno e vasculites. in: Insuficiencia Renal Aguda, edited by O da Rosa Santos, Revinter, Rio de Janeiro, Brazil, 1992, pp 238-245.
20. Kimberly RP: Steroid use in lupus erythematosus. in: Systemic Lupus Erythematosus, edited by RG Lahita, Churchill-Livingston, New York, 1993, pp 907-932.
21. Kimberly RP: Use of corticosteroids in the acutely ill patient. in: Acute Rheumatic and Immunological Diseases: Management of the Critically Ill patient, edited by BF Mandell, Marcel Dekker, New York, 1994, pp 527-539.
22. Kimberly RP: Section Editor, Connective Tissue Disorders. in: Rheumatology, edited by JH Klippel and PA Dieppe, Mosby-Year Book Europe Ltd, London, 1994, pp 6.1.1 - 6.33.2.

23. Edberg JC, Salmon JE, Porges AJ, Kimberly RP: SLE: Immunopathology. in: Rheumatology, edited by JH Klippel and PA Dieppe, Mosby Yearbook Europe Ltd, London, 1994, pp 6.3.1 -6.3.12.
24. Salmon JE, Edberg JC, Kimberly RP: Fc Receptors on Neutrophils. in: Human IgG Fc Receptors, edited by JGJ van de Winkel and PJA Capel, RG Landes Company (Molecular Biology Intelligence Unit), 1995.
25. Kimberly RP. Characteristics of Immune Complexes and the Principles of Immune Complex Disease. in: Arthritis and Allied Conditions: W J Koopman, editor, 14th Edition. Lippincott, Williams & Wilkins, Philadelphia, 1997, pp 529-543.
26. Kimberly RP: Section Editor, Connective Tissue Disorders. in: Rheumatology, edited by JH Klippel and PA Dieppe, Mosby-Year Book Europe Ltd, London, 1997, pp 7.1.1 - 7.33.
27. Edberg JC, Salmon JE, Kimberly RP: SLE: Immunopathology. in: Rheumatology, edited by JH Klippel and PA Dieppe, Mosby Yearbook Europe Ltd, London, 1997, pp 7.4.1 - 7.4.12.
28. Salmon JE and Kimberly RP: Fcγ Receptor Polymorphisms. in: *Human IgG Fc Receptors*, J.G.J. van de Winkel and P.M. Hogarth (editors), Molecular Biology Intelligence Unit series, R.G. Landes Company, Austin, TX, 1998, pp 267-278.
29. Kimberly RP. Corticosteroid Use in Systemic Lupus Erythematosus. in: Systemic Lupus Erythematosus, Third Edition, RG Lahita, editor. Academic Press, NY, 1998, pp 945-966.
30. Gibson AW, Wu J, Edberg JC, Kimberly RP. Fcγ receptor polymorphisms, insight into pathogenesis. in: Lupus - Cellular and Molecular Pathogenesis, G Kammer and GC Tsokos, editors. Humana Press, Totowa, NJ, 1999, pp 557-573.
31. Kimberly RP: Genetics of Human Lupus. in: Genes and Genetics of Autoimmunity. Curr Dir Autoimmunity. AN Theofilopoulos, editor. Karger, Basel, 1999, pp 99-120.
32. Chatham WW, Edberg JC, Kimberly RP. Roles of Neutrophils. in: Rheumatoid Arthritis: Frontiers in Pathogenesis and Treatment. G Firestein, G Panayi, F Wollheim, editors. Oxford University Press, Oxford, 2000, pp 101-112.
33. Kimberly RP. Gene Therapy in Rheumatic Diseases. in: Principles of Molecular Rheumatology. GC Tsokos, editor. Human Press, Totowa, NJ, 2000. pp 515 - 523.
34. Bridges SL Jr and Kimberly RP. Genetic Influences on Treatment Response in Rheumatoid Arthritis. in: Modern Therapeutics in Rheumatic Diseases. Tsokos G, editor. Humana Press, Inc., Totowa, NJ, 2001, pp 11-22.
35. Jones RE, Kimberly RP. Pulse Corticosteroid Therapy. in: Principles of Corticosteroid Therapy, AN Lin and SA Paget, editors. Arnold, London, 2002. pp 431- 440.
36. Kimberly RP. Fc Receptors in Vascular Diseases. in: Inflammatory Diseases of Blood Vessels. GS Hoffman and CM Weyand, editors. Marcel Dekker, NY, 2002. pp113 – 126.

37. Kimberly RP. Fc Receptors in Disease. in: Kelley's Textbook of Rheumatology: Updates (1:4) S Ruddy, E Harris, Jr., CB Sledge, Editors. W. B. Saunders Company, Philadelphia, PA, 2002.
38. Salmon JE, Kimberly RP, D'Agati V. Immunopathology. in: Rheumatology. MC Hochberg, AJ Silman, JS Smolen, ME Weinblatt, MH Weisman, Editors, 3rd Edition. Mosby, Philadelphia, 2003, pp 1297-1316.
39. Zhou T, Zhang J, Carter R, Kimberly R. BLyS and B cell autoimmunity. Curr Dir Autoimmun 6:21-37, 2003.
40. Gibson A, Edberg JC, Wu J, Kimberly RP. Interleukin-10: Genetic polymorphisms and relevance to autoimmune pathology. in: IL-10, edited by F. Marincola, Landes Biosciences, Georgetown, Texas. In press, 2004 (posted electronically 12/03).
41. Shanahan J, Kimberly RP. Corticosteroid Use in Systemic Lupus Erythematosus. in: Systemic Lupus Erythematosus, Fourth Edition, RG Lahita, editor. Academic Press, NY, In press, 2004.
42. Kimberly RP. Characteristics of Immune Complexes and the Principles of Immune Complex Disease. in: Arthritis and Allied Conditions. W J Koopman, editor, 15th Edition. Lippincott, Williams & Wilkins, Philadelphia, In press, 2004.

Published abstracts

1. Kimberly RP, Gill JR Jr, Bowden RE, Plotz PH: Effect of aspirin on renal blood flow, glomerular filtration rate and renal prostaglandin in systemic lupus erythematosus. Arthritis Rheum 20: 123, 1977.
2. Kassan SS, Hoover R, Kimberly RP, Budman DR, Decker JL, Chused TM: Increased incidence of malignancy in Sjogren's syndrome. Arthritis Rheum 20: 123, 1977.
3. Bowden RE, Kimberly RP, Gill JR Jr, Plotz PH, Keiser HR: Urinary prostaglandin E and renal function. Clin Res 25: 427A, 1977.
4. Frank MM, Jaffe CJ, Kimberly RP, Lawley TJ, Plotz PH: An immunospecific clearance defect in patients with systemic lupus erythematosus (SLE) related to the levels of circulating immune complexes. Clin Res 25: 375A, 1977.
5. Kimberly RP, Bowden RE, Keiser HR, Plotz PH: Urinary prostaglandin E in systemic lupus erythematosus. Clin Res 26: 380A, 1978.
6. Kimberly RP, Bowden RE, Keiser HR, Plotz PH: Urinary prostaglandin E and clinical status in systemic lupus erythematosus. Arthritis Rheum 21: 570, 1978.
7. Kimberly RP, Lockshin MD, Sherman RL, McDougal JS, Steinman C, Christian CL: Acute corticosteroid-induced depression of renal function in systemic lupus erythematosus. Arthritis Rheum 22: 629, 1979.

8. Kimberly RP, Lockshin MD, Sherman RL, McDougal JS, Inman RD, Christian CL: Clinical efficacy of high-dose intravenous methylprednisolone therapy in systemic lupus erythematosus. *Arthritis Rheum* 22: 629, 1979.
9. Beary J, Lockshin M, Sherman R, Mouradian J, Cheigh J, Kimberly RP: Renal dialysis in systemic lupus erythematosus: predictive factors and outcome in 35 patients. *Arthritis Rheum* 22: 591, 1979.
10. Kimberly RP, McDougal JS, Inman RD, Lockshin MD, Sherman RL: Immune complex levels and response to high-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. *Clin Res* 28: 606A, 1980.
11. Kimberly RP, Inman RD, McDougal JS, Lockshin MD, Sherman RL, Christian CL: Dynamics of renal function in lupus nephritis: predictive value and implications of drug-induced transient changes. *Arthritis Rheum* 23: 703, 1980.
12. Parris TM, Kimberly RP, Inman RD, Davey M, Korngold L: Reticuloendothelial system Fc receptor function in systemic lupus erythematosus (SLE): Renal and nonrenal subsets. *Clin Res* 29: 160A, 1981.
13. Kimberly RP, Lockshin MD, Sherman RL, Mouradian J, Saal S: Reversible "end-stage" renal disease in lupus nephritis. *Arthritis Rheum* 24: S121, 1981.
14. Kimberly RP, Scheer L: Acute corticosteroid-induced depression of renal function in systemic lupus erythematosus: association with decreased renal prostaglandin synthesis. *Arthritis Rheum* 24: S107, 1981.
15. Schned ES, Inman RD, Parris TM, Kimberly RP, Redecha PB, Christian CL: Serial circulating immune complexes and reticuloendothelial system Fc-receptor function in infectious endocarditis. *Arthritis Rheum* 24: S74, 1981.
16. Hamburger MI, Field TR, Lawley TJ, Hall R, Kimberly RP, Plotz P, Frank MM: Reticuloendothelial system C3b receptor function in systemic lupus erythematosus. *Arthritis Rheum* 24: S81, 1981.
17. Parris TM, Kimberly RP, Inman RD, Davey MP, Korngold L: Reticuloendothelial system Fc receptor function in SLE: Differences between renal and nonrenal subsets. *Arthritis Rheum* 24: S58, 1981.
18. Parris TM, Kimberly RP, Inman RD: Dynamics of reticuloendothelial system Fc receptor function in SLE: Changes associated with alterations in disease activity. *Arthritis Rheum* 24: S120, 1981.
19. Kimberly RP, Scheer L: Renal prostaglandin E2 (PGE2) synthesis in SLE: Relation to activity of renal disease. *Arthritis Rheum* 25: S45, 1982.
20. Kimberly RP, Inman RD, Bussel JB, Hilgartner MW, Christian CL: Modulation of Fc receptor (FcγR) dependent mononuclear phagocyte system (MPS) function: Effects of Factor VIII infusion in hemophilia. *Arthritis Rheum* 25: S72, 1982.

21. Kimberly RP, Inman RD, Bussel JB, Smithwick E, Cunningham-Rundles C, Hilgartner MW, Christian CL: Modulation of Fc γ receptor (Fc γ R) dependent mononuclear phagocyte system (MPS) function: Effects of intravenous Swiss Red Cross Ig (IgSRK) in idiopathic thrombocytopenic purpura (ITP). *Arthritis Rheum* 25: S72, 1982.
22. Bussel J, Kimberly R, Inman R, Hilgartner M, Cheung N, O'Malley J, Salmon J, Barandun S: Intravenous gammaglobulin for chronic autoimmune thrombocytopenia. *Blood* 60: 185A, 1982.
23. Salmon JE, Kimberly RP, Bussel JB, Hilgartner MW: Concomitant in vivo and in vitro mononuclear phagocyte system (MPS) Fc receptor (Fc γ R) dysfunction induced by intravenous gammaglobulin (IgSRK). *Clin Res* 31: 160A, 1983.
24. Kimberly RP, Gibofsky A, Salmon JE, Fotino M: Impaired Fc-mediated mononuclear phagocyte system clearance in HLA-DR2 and MT1-positive normals. *Clin Res* 31: 347A, 1983.
25. Salmon JE, Kimberly RP: Defective mononuclear phagocyte function in vivo and in vitro in systemic lupus erythematosus. *Arthritis Rheum* 26: S36, 1983.
26. Kimberly RP, Gibofsky A, Salmon JE, Fotino M: Impaired Fc-mediated mononuclear phagocyte system clearance in HLA-DR2 and MT1-positive normals. *Arthritis Rheum* 26: S36, 1983.
27. Bussel JB, Schulman I, Kimberly RP, Hilgartner MW: Intravenous gammaglobulin treatment of chronic ITP to prevent splenectomy. *American Pediatrics Society*, 1983.
28. Kimberly RP, Tappe N, Riggs-Dobbs C, Salmon JE: Prostaglandin E2 production by monocytes in systemic lupus erythematosus. *Clin Res* 32: 663A, 1984.
29. Kimberly RP, Tappe N, Dobbs C, Attenbury BT, Salmon JE: Arachidonic acid metabolism by monocytes in systemic lupus. *Arthritis Rheum* 27: S83, 1984.
30. Salmon JE, Kimberly RP, Gibofsky A, Fotino M: Altered phagocytosis by monocytes from HLA DR2 positive normals is Fc γ receptor mediated. *Arthritis Rheum* 27: S56, 1984.
31. Bussel J, Morrell A, Porges A, Skvaril F, Barandun S, Kimberly R, Hilgartner M: Selective IgG2 deficiency in patients with ITP. *Blood* 64: 235a, 1984.
32. Bussel J, Porges A, Kimberly R, Schulman I, Pollach M, Pandley J, Hilgartner M: DR3 in patients with chronic ITP: Increased levels of platelet-associated antibodies in these patients. *Blood* 64: 235a, 1984.
33. Kimberly RP, Meryhew NL, Messner RP, Runquist OA: A model for immune complex diseases in SLE: Bipartite Fc γ receptor and complement dependent dysfunction. *Clin Res* 33: 508A, 1985.
34. Salmon JE, Kimberly RP, Gibofsky A, Tappe N, Fotino M: Concanavalin-A mediated phagocytosis: an Fc γ -receptor related function. *Clin Res* 33: 512A, 1985.

35. Kimberly RP, Redecha P, Prendergast TM, Greisman S: Lectins and the Fc receptor: affinity isolated Fc- receptor binds Concanavalin-A. *Arthritis Rheum* 28: S71, 1985.
36. Merriam LT, Kimberly RP: Impaired phagocytosis by young autoimmune murine splenocytes. *Arthritis Rheum* 28: S99, 1985.
37. Chatpar PC, Kimberly RP, Falcone DJ, Christian CL: Lipoprotein handling by abnormal macrophages of autoimmune MRL/lpr lupus-like mice. *Arthritis Rheum* 28: S63, 1985.
38. Clarkson SB, Kimberly RP, Bussel JB, Nachman LR, Valinsky J, Unkeless JC: Blockade of immune complex clearance by an anti-Fc γ receptor monoclonal antibody. *Clin Res* 33: 374A, 1985.
39. Clarkson S, Bussel J, Kimberly R, Valinsky J, Unkeless J, Nachman R: Platelet increase in refractory ITP after infusion of monoclonal anti-Fc γ receptor antibody. *Blood* 66: 287a, 1985.
40. Merriam LT, Kimberly RP: Complement-mediated phagocytosis by autoimmune murine mononuclear phagocytosis is enhanced. *Arthritis Rheum* 29: S10, 1986.
41. Kapur S, Salmon JE, Kimberly RP: Gammaglobulin for intravenous use induces an Fc γ receptor-mediated deficit in phagocytosis by blood monocytes. *Arthritis Rheum* 29: S10, 1986.
42. Clarkson SB, Kimberly RP, Witmer M, Bussel JB, Valinsky J, Nachman RL, Unkeless JC: Blockade of model immune complex clearance by monoclonal anti-Fc γ receptor antibody. *Arthritis Rheum* 29: S73, 1986.
43. Salmon JE, Kimberly RP: Pulse methylprednisolone increases Fc γ receptor-mediated phagocytosis in systemic lupus erythematosus. *Arthritis Rheum* 29: S97, 1986.
44. Kimberly RP, Meryhew NL, Runquist OA: Complement-mediated mononuclear phagocyte system clearance function is decreased in normocomplementemic rheumatoid arthritis. *Arthritis Rheum* 29: S41, 1986.
45. Salmon JE, Kimberly RP: Pulse methylprednisolone increases Fc γ receptor-mediated phagocytosis in systemic lupus erythematosus. *Clin Res* 34: 422A, 1986.
46. Schwartzman S, Redecha PB, Merriam LT, Kimberly RP: Human Fc γ receptor structure: a polyclonal anti-neutrophil FcR antibody immunoblots with monocyte Fc γ R. *Arthritis Rheum* 30: S48, 1987.
47. Salmon JE, Kapur S, Kimberly RP: Phagocytosis of concanavalin A- treated erythrocytes (E-ConA) and non-opsonized E. coli by neutrophils is mediated by Fc γ receptors. *Arthritis Rheum* 30: S72, 1987.
48. Kimberly RP, Clarkson SB, Merriam LT, Edberg JC, Unkeless JC, Taylor RP: Antibody/dsDNA immune complex handling in primates: the role of complement and Fc γ

- receptor-mediated mechanisms. *Arthritis Rheum* 30: S102, 1987.
49. Salmon JE, Mensa E, Ryan R, Kimberly RP: Functional significance of the NA1-NA2 polymorphism of the Fc γ RIII in neutrophils. *Arthritis Rheum* 31: S43, 1988.
 50. Salmon JE, Mensa E, Ryan R, Kimberly RP: Functional significance of the NA1-NA2 polymorphism of the Fc γ RIII in neutrophils. *Clin Res* 36: 537A, 1988.
 51. Bussel J, Kimberly RP, Nachman R, Unkeless J: Monoclonal antibody treatment of patients with refractory ITP. *Blood* 72: 262a, 1988.
 52. Edberg JC, Barinsky M, Salmon JE, Kimberly RP: Analysis of CD16 (Fc γ RIII) and lipid-linked markers in PNH. *Arthritis Rheum* 32: S147, 1989.
 53. Edberg JC, Redecha PB, Salmon JE, Kimberly RP: Molecular isoforms and allelic forms of Fc γ RIII. *Arthritis Rheum* 32: S147, 1989.
 54. Salmon JE, Mensa E, Kimberly RP: Internalization of Concanavalin A- treated erythrocytes by neutrophils requires Fc γ receptor III, not Fc γ receptor II. *Arthritis Rheum* 32: S146, 1989.
 55. Kimberly RP, Ahlstrom JW, Click ME: Fc receptor III on human neutrophils mediates transmembrane signaling events distinct from Fc γ receptor II. *Arthritis Rheum* 32: S124, 1989.
 56. Kimberly RP, Edberg JC, Clarkson SB, Taylor RP: The transfer reaction: The role of Fc γ receptors in the uptake of erythrocyte-bound immune complexes by phagocytes in primates. *Arthritis Rheum* 32: S147, 1989.
 57. Edberg JC, Redecha PB, Salmon JE, Kimberly RP: Molecular isoforms and allelic variants of Fc γ RII, 7th International Congress of Immunology, Abst #19-8, p 105, 1989.
 58. Kimberly RP, Edberg JC, Ahlstrom JW, Click ME, Triscari C: Analysis of CD16 (Fc γ RIII) structure and function, 7th International Congress of Immunology, Abst #19-23, p 107, 1989.
 59. Bussel J, Khayat D, Cunningham-Rundles S, Kimberly R, Nachman R, Unkeless J: Alleviation of cytopenias in 3 HIV infected patients with infusion of a monoclonal anti-Fc γ RIII antibody. *Blood* 74: 89a, 1989.
 60. Salmon JE, Brogle N, Edberg JC, and Kimberly RP: Fc γ receptor II and Fc γ receptor III can independently induce actin polymerization in human neutrophils. *Clin Res* 38: 317A, 1990.
 61. Edberg JC, Barinsky M, Redecha PB, Salmon JE, Kimberly RP: Differences in glycosylation between Fc γ RIII expressed on cultured monocytes and NK cells influence the ligand binding site. *Arthritis Rheum* 33: S108, 1990.
 62. Edberg JC, Barinsky M, Redecha PB, Salmon JE, Kimberly RP: Fc γ RIII expressed on cultured monocytes is an N-glycosylated transmembrane protein: Similarity to Fc γ RIII expressed on NK cells. *FASEB J* 4: A2179, 1990.

63. Salmon JE, Brogle N, Edberg JC, and Kimberly RP: Ligation of Fc γ receptor (Fc γ R) III enhances phagocytosis by Fc γ RII. *Arthritis Rheum* 33: S111, 1990.
64. Kimberly RP, Click ME, Edberg JC, Salmon JE, Brogle N, and Ahlstrom JW: Stable individual differences in receptor-induced [Ca²⁺]_i fluxes do not correlate with functional differences of Fc γ RIIIPMN alleles. *Arthritis Rheum* 33: S108, 1990.
65. Kimberly RP, Salmon JE, Edberg JC, Shen L, Barinsky M, Brogle N, and Triscari C: The HLA class II-associated differences in Fc R-mediated phagocytosis are mediated by Fc γ RI. *Arthritis Rheum* 33: S108, 1990.
66. Edberg JC, Barinsky M, and Kimberly RP: The GPI-linked Fc γ RIII functions synergistically with Fc γ RII on PMN. *FASEB J* 5: A1463, 1991.
67. Salmon JE, Edberg JC, Brogle NL, and Kimberly RP: Functional consequence of allelic variants of Fc γ receptors (Fc γ R) on human phagocytes. *FASEB J* 5: A1718, 1991.
68. Kimberly RP, Edberg JC, Redecha PB, and Barinsky M: Fc RIII-A glycoforms have distinct affinities for ligand. *FASEB J* 5: A1346, 1991.
69. Porges AJ, Beattie SL, Ritchlin C, Kimberly RP, and Christian CL: Patients with systemic lupus at increased risk for pneumocystis carinii pneumonia. *Arthritis Rheum* 34: S97, 1991.
70. Porges AJ, Redecha PB, Pan L, Knowles R, Edberg J, Salmon J, and Kimberly RP: Amplification and expression of human Fc γ RI polymorphisms. *Arthritis Rheum* 34: S168, 1991.
71. Edberg JC, Salmon JE, and Kimberly RP: The GPI-linked Fc γ RIII functions synergistically with Fc γ RII on PMN. *Arthritis Rheum* 34: S167, 1991.
72. Salmon JE, Edberg JC, Brogle N, and Kimberly, RP: Functional consequences of allelic variants of Fc γ receptors on human phagocytes. *Arthritis Rheum* 34: S165, 1991.
73. Porges AJ, Redecha PB, Pan LC, Edberg JC, Salmon JE, Kimberly RP: Amplification and expression of a novel human Fc γ RI polymorphism. *Clin Res* 40: 342A, 1992.
74. Huang R, Cioffi J, Kimberly R, Mayer L. Response to a human B cell differentiation factor results in the release of intracellular calcium. *FASEB J* 6: A1411, 1992.
75. Porges AJ, Redecha P, Kimberly RP: Anti-neutrophil cytoplasmic antibodies (ANCA) engage neutrophil Fc γ receptor II. *Arthritis Rheum* 35: S115, 1992.
76. Edberg JC, Levine J, Kimberly RP: Differential effects of interferon α and transforming growth factor (TGF) on human Fc γ R with the MIRR signaling motif. *Arthritis Rheum* 35: S42, 1992.
77. Edberg JC, Moon JJ, Kimberly RP: Functional synergism between human neutrophil Fc γ RII and Fc γ RIII (#361). *J Immunol* 150: 65A, 1993.

78. Porges A, Redecha P, Pan L, Kimberly R: Amplification and expression of a novel human Fc γ receptor IA gene transcript (#360). *J Immunol* 150: 65A, 1993.
79. Indik ZK, Hunter S, Chien P, Pan XQ, Kimberly RP, Huang MM, Levinson AI, Schreiber AD: The high affinity Fc γ receptor (CD64) induces phagocytosis in the absence of its cytoplasmic domain. *Clin Res* 41: 170A, 1993.
80. Salmon JE, Kimberly RP: Enhancement of Fc γ RII-mediated internalization by Fc γ RIIIB in neutrophils is oxidant-dependent and allele-sensitive. *Clin Res* 41: 243A, 1993.
81. Chang DJ, Edberg JC, Moon JJ, Kimberly RP: Differential regulation of human neutrophil Fc γ RII and Fc γ RIII early signal transduction events. *Arthritis Rheum* 36: S244, 1993.
82. Siegel ME, Chang DJ, Kimberly RP: The activated, pro-adhesive PMN phenotype: preferential effects of separate Fc γ receptor families. *Arthritis Rheum* 36: S244, 1993.
83. Salmon JE, Brogle N, Kimberly RP: Enhancement of Fc RII-mediated internalization by Fc γ RIIIB in neutrophils is oxidant-dependent and allele-sensitive. *Arthritis Rheum* 36: S47, 1993.
84. Edberg JC, Moon JJ, Kimberly RP: PMN activation by Fc γ RIII utilizes distinct signaling pathways. *Arthritis Rheum* 36: S70, 1993.
85. Porges AJ, Redecha PB, Csernok E, Gross WL, Kimberly RP: Monoclonal anti-neutrophil cytoplasmic antibodies engage and activate neutrophils via Fc γ RIIA. *Arthritis Rheum* 36: S84, 1993.
86. Runquist O, Head M, Johann J, Kimberly R, Meryhew N: Mechanism and computer simulation predicts disease activity in SLE. *Arthritis Rheum* 37: S134, 1994.
87. Salmon JE, Millard SS, Arnett FC, Ramsey-Goldman R, McKenzie S, Reilly A, Kimberly RP: Fc γ RIIa is a non-MHC heritable risk factor for SLE in African-Americans. *Arthritis Rheum* 37: S50, 1994.
88. Salmon JE, Millard SS, Ginzler EM, Arnett FC, Ramsey-Goldman R, Gourley MF, Schur P, Kimberly RP: Fc γ RIIa is a non-MHC heritable risk factor for SLE in African-Americans. *J Invest Med* 43: 332A, 1995.
89. Edberg JC, Lau D, Mohile N, Lin CT, Unkeless JC, Kimberly RP: [Ca²⁺]_i dependence of Fc γ receptor initiated signaling for phagocytosis. *FASEB J* 9: A805, 1995.
90. Wainstein E, Edberg JC, Dow D, Csernok E, Sneller M, Keystone E, Gross W, Hoffman G, Kimberly RP: Fc γ RIIb alleles are significantly skewed in Wegener's Granulomatosis (WG). Sixth International ANCA Workshop, 1995; and *Arthritis Rheum*, 38:S375, 1995.
91. Yee AMF, Chang DJ, Leonard JT, Lau D, Indik Z, Schreiber AD, Edberg JC, Kimberly RP: The Fc γ RI α -chain which lacks a tyrosine activation motif (TAM) influences receptor initiated tyrosine phosphorylation. *Arthritis Rheum*, 38:S190, 1995.

92. Salmon JE, Millard S, Schachter L, Ginzler EM, Ramsey-Goldman R, Gourley MF, Arnett C, Kimberly RP: FcγRIIA alleles are heritable risk factors for lupus nephritis in African-Americans. *Arthritis Rheum*, 38:S398, 1995.
93. Kocher M, Edberg J, Fleit H, Kimberly RP: Anti-neutrophil cytoplasmic antibody (ANCA) engagement of FcγRIIb on neutrophils (PMN) is blocked by soluble Fcγ receptor. *Arthritis Rheum*, 39:S210, 1996.
94. Wainstein E, Edberg J, Csernok E, Sneller M, Hoffman G, Keystone E, Gross W, Salmon J, Kimberly RP: FcγRIIIB alleles predict renal dysfunction in Wegener's granulomatosis (WG). *Arthritis Rheum*, 39:S210, 1996.
95. Schachter LA, Wisnieski JJ, Denburg MR, Michael AR, Ginzler EM, Gourley MF, Salmon JE, Kimberly RP: Antibodies to the collagen like region of C1q in systemic lupus erythematosus. *Arthritis Rheum*, 39:S210, 1996.
96. Kuo A, Gadaleta SJ, Raman C, Kimberly RP: The cell surface molecule, CD5, associates with casein kinase II. *Arthritis Rheum* 39:S264, 1996.
97. Yee AMF, Lau D, Edberg JC, Kimberly RP: Activation of the human high affinity IgG receptor (FcγRI) requires serine dephosphorylation of its cytoplasmic domain. *Arthritis Rheum*, 39:S312, 1996.
98. Wu J, Bansal V, Arnett F, Reveille J, Ginzler E, Gourley M, Ramsey-Goldman R, Salmon J, Edberg J, Kimberly R: The FcγRIIA 176F/V polymorphism associates with the SLE phenotype in caucasians and African Americans (AA). *Arthritis Rheum*, 40:S316, 1997.
99. Wu J, Bansal V, Redecha P, Coleman K, Guyre P, Salmon J, Edberg J, Kimberly R: A novel polymorphism of FcγRIIA alters receptor affinity and antibody-dependent function. *Arthritis Rheum*, 40:S72, 1997.
100. Kocher M, Edberg J, Kimberly R: Anti-neutrophil cytoplasmic antibodies (ANCA) induce adhesion receptor changes on neutrophils (PMN). *Arthritis Rheum*, 40:S68, 1997.
101. Yee AMF, Redecha PB, Edberg JC, Kimberly RP: Signaling by the human high affinity IgG receptor (FcγRIa) requires the interaction of its cytoplasmic domain with HCK. *Arthritis Rheum*, 40:S126, 1997.
102. Moreland LW, Alarcón GS, Kimberly RP: European (EU) and US rheumatologists (RHEUM) agree in triple but not on double or single early DMARD choice for different types of RA. *Arthritis Rheum*, 40:S218, 1997.
103. Wu J, Edberg JC, Gibson AW, Tsao B, Kimberly RP: Polymorphisms and mutations of TCR Zeta and FcR gamma chain of SLE Patients. *Arthritis Rheum*, 41:S142, 1998.
104. Edberg JC, Chen K, Wu J, Salmon JE, Kimberly RP: FcγRIIb Alleles predict renal dysfunction in Wegener's Granulomatosis (WG) but not SLE. *Arthritis Rheum*, 41:S141, 1998.

105. Edberg JC, Kocher M, Fleit H, Kimberly RP: Anti-neutrophil cytoplasmic antibodies (ANCA) preferentially engage Fc γ RIIIb on neutrophils. *Arthritis Rheum*, 41:S243, 1998.
106. Kimberly RP, Moreland LW, Gibson AW, Weinblatt M, Blosch C: Susceptibility to infection may vary with TNF promoter genotype. *Arthritis Rheum*, 41:S273, 1998.
107. Kimberly RP, Moreland LW, Wu J, Edberg JC, Weinblatt M, Blosch C: Occurrence of infection varies with Fc γ receptor genotype. *Arthritis Rheum*, 41:S273, 1998.
108. Wu J, Edberg JC, Gibson AW, Mangan-Schultz EK, Kimberly RP: A novel polymorphism of the CCAAT/Enhancer-Binding Protein β (C/EBP β) Element in the FasL gene promoter significantly alters biological function and may predispose to SLE. *Arthritis Rheum*, 42:S202, 1999.
109. Mangan-Schultz EK, Edberg JC, Kimberly RP: The cytoplasmic domain of Fc γ RIIIa interacts with the S100 protein family. *Arthritis Rheum*, 42:S192, 1999.
110. Gibson AW, Keijsers V, Edberg JC, Huizinga TWJ, Kimberly RP: Novel genetic polymorphisms in the IL-10 promoter. *Arthritis Rheum*, 42:S91, 1999.
111. Edberg JC, Moser KL, Zhu Y, Chen K, Salmon JE, Gray-McGuire C, Yu H, Neas B, Harley JB, Kimberly RP: Genetic association at Fc γ receptor IIIA (CD16A) on Chromosome 1q23 with human Systemic Lupus Erythematosus. *Arthritis Rheum*, 42:S386, 1999.
112. Du Clos TW, Mold C, Bharadwaj D, Edberg JC, Stein MP, Kimberly RP: C-Reactive protein binding to Fc γ RIIa on human monocytes and neutrophils is allele-specific. *Arthritis Rheum*, 42:S274, 1999.
113. Zhang J, Roschke V, Baker, KP, Wang Z, Alarcon GS, Fessler BJ, Bastian H, Kimberly RP, Zhou T: Role for B lymphocyte stimulator (BlyS) in Systemic Lupus Erythematosus. *Arthritis Rheum*, 43:S94, 2000.
114. Harley J, Gray-McGuire C, Kelly J, Salmon J, Kimberly RP, Edberg JC, Neas BR, Bruner GR, Olson JM, Moser KL: Seven established linkages to human Systemic Lupus Erythematosus. *Arthritis Rheum*, 43: S279, 2000.
115. Huizinga TWJ, van der Linden MW, Eskdale J, Vergouwe M, Lard LR, de Jong BA, Gallagher G, Kimberly RP, Breedveld FC, Westendorp RGJ: A single nucleotide polymorphism on the IL 10 locus defines an expression polymorphism and a risk factor to develop Rheumatoid Arthritis (RA). *Arthritis Rheum*, 43: S326, 2000.
116. Mangan EK, Edberg, JC, Chen K, Kimberly RP: Genetic differences in the binding of a humanized IgG4 MAB to Fc γ RIIIa. *Arthritis Rheum*, 43: S355, 2000.
117. Gibson AW, Edberg JC, Tan FK, Reveille JD, Lisse JR, Alarcón GS, Kimberly RP: Association between IL-10 microsatellite alleles and Systemic Lupus Erythematosus in different ethnic groups. *Arthritis Rheum*, 43: S359, 2000.

118. Reveille JD, Gibson AW, Tan FK, Edberg JC, Lisse JR, Friedman AW, Fessler BJ, Bastian HM, Kang SH, Kimberly RP, Alarcón GS: II10 and *bc1-2* microsatellite alleles in Systemic Lupus Erythematosus (SLE) patients: *bc1-2* independently influences disease activity. *Arthritis Rheum*, 43:S359, 2000.
119. Tanaka S, Edberg JC, Chatham WW, McDuffie D, Kimberly RP: Genetic difference in quantitative Fcγ receptor mediated neutrophil degranulation. *Arthritis Rheum*, 43: S388, 2000.
120. Ichikawa K, Liu WM, Zhang HG, Mountz JD, Koopman WJ, Kimberly RP, Zhou T: Induction of apoptosis of RA synovial cells by a novel anti-human DR5 antibody. *Arthritis Rheum*, 43:S398, 2000.
121. Harley J, Gray-McGuire C, Kelly J, Salmon J, Kimberly RP, Edberg JC, Neas BR, Bruner GR, Olson JM, Moser KL: Genetic linkages with lupus in Americans of African and European ancestry. 13th NATO Conference on Molecular Biological Approaches for Intractable Diseases [11], November 8-11, 2000.
122. Harley J, Kelly J, Kaufman K, Gray-McGuire C, Salmon J, Kimberly RP, Edberg JC, Bruner GC, Olson JM, Moser KL: Genetics of human lupus. B Cell Workshop, Bergen, Norway, July 2001.
123. Chatham WW, Liu W, Kimberly RP, Zhou T, Carter RH: B Lymphocyte stimulator and its receptors on B cells form a potential positive loop in SLE. *Arthritis Rheum*, 44:S277, 2001.
124. Su K, Edberg JC, Wu J, McKenzie SE, Kimberly RP: Single nucleotide polymorphisms in the FcγRIIB gene promoter which alter receptor expression and associate with Systemic Lupus Erythematosus in African Americans. *Arthritis Rheum*, 44:S1170, 2001.
125. Mariette X, Roux S, Desmoulins F, Gottenberg JE, Zhang J, Zhou T, Kimberly RP: A role for B lymphocyte stimulator (BLyS) in Sjögren's syndrome. *Arthritis Rheum*, 44:S1205, 2001.
126. Sanchez ML, Copeland RM, McGwin, Jr G, Fessler BJ, Sowell E, Kimberly RP, Alarcon GS: Does the use of the weighted criteria improve our ability to capture larger number of lupus patients into observational and interventional studies than the ACR criteria? *Arthritis Rheum*, 44:S1672, 2001.
127. Miranda-Carus ME, Kimberly RP, Edberg JC, Buyon JP: FcγR allelic polymorphisms: a candidate fetal factor in the development of congenital heart block (CHB). *Arthritis Rheum*, 44:S1726, 2001.
128. Tanaka S, Edberg JC, Fassina G, Kimberly RP: Blockade of antineutrophil cytoplasmic antibody (ANCA) activation of neutrophils by a therapeutic peptide. *Arthritis Rheum*, 44:S1749, 2001.
129. Tanaka S, Edberg JC, Fassina G, Kimberly RP: Antineutrophil cytoplasmic antibodies (ANCA) induce release of human neutrophil α-defensins: T cell and dendritic cell recruitment factors. *Arthritis Rheum*, 44:S1750, 2001.

130. Liu W, Zhao L, Wang Z, Ichikawa K, Chatham WW, Szalai A, Carter RH, Kimberly RP, Zhou T: An agonistic anti-human DR5 antibody in treatment of autoimmune disease. *Arthritis Rheum*, 44:S1906, 2001.
131. Kimberly RP, Langefeld CD, Moser KL, Gaffney PM, Kelly J, Graham RR, Brown WM, Rich SS, Harley JB, Behrens TW, for the SCOR in the Genetics of SLE. The lupus SCOR combined genome scan: Identification of three major susceptibility regions. *Arthritis Rheum*, 44:S2037, 2001.
132. Edberg JC, Langefeld CD, Moser KL, Kelly J, Kaufman JM, Rich SS, Harley JB, Kimberly RP, for the SCOR in the Genetics of SLE. Linkage and association of a functional single nucleotide polymorphism (SNP) in the FcγRIIIA gene with SLE. *Arthritis Rheum*, 44:S2040, 2001.
133. Zhou T, Martin F, Liu W, Zhao L, Kimberly RP, Carter RH: Adenoviral delivery of TACI-Fc reverses autoimmunity in mice. *Arthritis Rheum*, 44:S2061, 2001.
134. Namjou B, Kilpatrick J, Kelly JA, Aberle T, Lam T, Reid J, Wilson J, Kimberly RP, Provost TT, James JA, Harley JB: Biopsy-proven Vasculitis is related to genetic linkages at 1p36 and 3p14-12 in Systemic Lupus Erythematosus (SLE). *Arthritis Rheum*, 15:S37, 2002.
135. Fessler BJ, Edberg JC, Bridges, Jr. SL, Beasley TM, Alarcon GS, Kimberly RP: Susceptibility of infection in patients with Systemic Lupus Erythematosus (SLE) varies with tumor necrosis factor (TNF) genotypes. *Arthritis Rheum*, 45:S59, 2002.
136. Tanaka S, Akahoshi T, Edberg JC, Kimberly RP, Kondo H: Enhancement of α-defensins release from human neutrophils by MPO-ANCA derived from microscopic polyangitis (MPA). *Arthritis Rheum*, 423:S189, 2002.